Claudin 18.2 expression profile in primary tumors and their ovarian metastases: implications for targeted therapy
The preserved expression of CLDN18.2 in metastatic tumors underscores its potential utility as a target for therapeutic approaches. Our findings emphasize the importance of evaluating CLDN18.2 status in both primary and metastatic tumors to refine therapeutic strategies.
Authors
- Ji Young Lee
- Sung Sun Kim (ORCID: https://orcid.org/0000-0002-8569-2178)
- Hyun Jin Bang
- Nah Ihm Kim
- Kyung‐Sub Moon (ORCID: https://orcid.org/0000-0002-1129-1064)
- Jae-Hyuk Lee (ORCID: https://orcid.org/0000-0002-9782-4297)
- Kyung‐Hwa Lee (ORCID: https://orcid.org/0000-0002-3935-0361)
- Tae Mi Yoon (ORCID: https://orcid.org/0000-0002-6070-9113)
- John Koo (ORCID: https://orcid.org/0009-0004-1005-5221)
- Ji Shin Lee (ORCID: https://orcid.org/0000-0002-0911-4587)
- Woo Kyun Bae
Institutions
- Chonnam National University Hwasun Hospital (KR)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-03-25
- DOI
- https://doi.org/10.1186/s12885-025-13940-4
- Citations
- 3
- Primary Topic
- Barrier Structure and Function Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.53
Funders
- National Research Foundation of Korea